Media & Investors
Get the latest news and discover our mission and vision. Meet our company speakers and get in touch for press and investor inquiries.
Get the latest news and discover our mission and vision. Meet our company speakers and get in touch for press and investor inquiries.
Read the latest of myTomorrows
September 9, 2024
CEO of myTomorrows, Michel van Harten M.D. discusses the dangerous implications of medical misinformation, not only for patients but also for healthcare professionals and the wider BioPharma industry.
September 4, 2024
Under a new partnership, CureLGMD2i will leverage myTomorrows' extensive search engine of ongoing clinical trials to provide patients, caregivers, and healthcare professionals with up-to-date, accessible information about pre-approval treatments that may be relevant to them.
September 3, 2024
Global health technology company myTomorrows announce a new partnership with Pancreatic Cancer Europe (PCE), a multi-stakeholder platform dedicated to improving care for pancreatic cancer patients.
August 27, 2024
Pancreatic cancer is notoriously challenging to treat, with a life expectancy of only 6-12 months at the time of diagnosis and a 5-year survival rate of just 10%. This partnership aims to enhance access to clinical trials for people suffering with pancreatic cancer by leveraging myTomorrows’ extensive search engine of ongoing trials.
July 1, 2024
Marshall Van Beurden, joins myTomorrows as Chief Technology Officer.. Van Beurden previously was the Managing Director for the Amazon Web Services (AWS) development center in the Netherlands and led the Enterprise Engineering team at Miro.
June 10, 2024
The US FDA recently announced a new initiative aimed at improving access to cancer trials among traditionally underserved populations. myTomorrows CEO Michel van Harten talked to Medtech Insight about how the agency’s plan might reshape the landscape of clinical trials going forward.
May 16, 2024
Jytte van Huijstee, Director of Clinical Trial Operations at myTomorrows, highlights the shift towards more patient-centric clinical trials. This approach focuses on designing trials that are more considerate of the patient’s needs and convenience, which can enhance patient recruitment and retention.
April 9, 2024
A new collaboration announced today will help provide brain tumour patients and physicians with accurate information about clinical trials in a bid to improve patient access.
April 9, 2024
Affecting 80,000 people in England, 12% of brain tumour patients survive beyond five years of diagnosis. myTomorrows has announced a new partnership with a UK-based charity, brainstrust, to support individuals living with brain cancer.
April 5, 2024
Affecting 80,000 people in England, 12% of brain tumour patients survive beyond five years of diagnosis. myTomorrows has announced a new partnership with a UK-based charity, brainstrust, to support individuals living with brain cancer.
April 4, 2024
myTomorrows and UK brainstrust plans to increase patient recruitment in brain tumour clinical trials by increasing awareness.
April 4, 2024
myTomorrows, a global health technology company connecting patients with all possible treatment options, today announced a new partnership with brainstrust, a UK-based charity that helps people living with a brain tumor reach their potential and thrive.
April 1, 2024
Certain features, commonplace on most e-commerce platforms, can help transform clinical trial search databases.
March 15, 2024
A non-profit organisation representing the amyotrophic lateral sclerosis (ALS) community in the US is taking a digital approach to connecting patients with suitable clinical trials.
March 14, 2024
Partnership with leading US-based ALS patient advocacy group furthers myTomorrows' mission of ensuring that patients confronting life-threatening diseases are aware of all possible treatment options
December 6, 2023
CEO Michel van Harten speaks with Clinical Trial Vanguard about myTomorrows’ innovative use of AI in physician-led clinical trial screening.
November 29, 2023
"I started myTomorrows in 2012 after losing my father to an aggressive form of lung cancer. As a physician and founder of several biotech companies, I thought I could help him find and access a treatment in development. But I was surprised at how complicated and slow the process was. I decided this had to change, so I dedicated myself to creating an easier and faster way for patients to access treatments in development.
We have grown a lot since then, and our team of experts has helped patients in over 60 countries. But our guiding principle remains the same: We believe every patient should have access to all possible treatment options. We are here for you, so let us know how we can help."
September 13, 2023
myTomorrows teams up with digital health innovator Congenica, highlighting tech’s role in the future of healthcare.
July 25, 2023
myTomorrows shares insights on discovering clinical trials for cancer.
June 28, 2023
myTomorrows’ CEO explores the power of AI for matching patients with the clinical trials right for them
April 27, 2023
Fierce Biotech shares launch of myTomorrows exciting new AI-backed patient pre-screening tool.
April 26, 2023
The global Health technology company myTomorrows said it launched the beta version of TrialSearch AI, a first-of-its-kind artificial intelligence tool to broaden physician insights into clinical trials and expanded access programs in the myTomorrows’ curated database.
Our experts have been pulled in to discuss a wide range of topics, from patient-centricity, clinical trials, expanded access, innovation, healthcare technology, artificial intelligence, and many more. Get in touch with them.
myTomorrows aims to break barriers for eligible patients seeking information about clinical trials and we support referrals to trial sites. When patients are not eligible to clinical studies, we can help them and their physicians to further explore and navigate the complexities of expanded access programs.
Our digital platform connects all stakeholders in pre-approval access and supports both clinical trial and expanded access workflows.
myTomorrows operates globally and has offices in Amsterdam and New York City.
We’ve helped
A community of
Trusted by
Media inquiries
mytomorrows@headline.media
